Is Monosomy of Chromosome 9 Linked to Adverse Outcomes in Renal Cell Carcinoma?
RTK Inhibitor Plus Immunotherapy in Advanced Kidney Cancer
FDA Accepts Biologics License Application for Proposed Biosimilar To Bevacizumab
GU Cancers Symposium 2020: Novel Agent May Inhibit Oncogenic Driver in Kidney Cancer
Combined Presence of Kidney Cancer and Myeloma: Two Clinical Cases
Metastatic Abscesses During Pazopanib Treatment: An Underdescribed Risk?
Perioperative Change in Renal Function: Prognostic Indicator in Renal Cell Carcinoma?
HIF-2α Protein and Progression of Clear Cell Kidney Cancer
Active Surveillance Safe for Small Renal Tumors
PD-1 Inhibitor Disappoints in mRCC With Untreated Brain Metastases
NCCN Guidelines® Insights – Kidney Cancer, Version 2.2020
NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
University of Wisconsin Carbone Cancer Center
University of Colorado Cancer Center
Duke Cancer Institute
Huntsman Cancer Institute at the University of Utah
Lenvatinib Plus Everolimus (Renal Cell Carcinoma)
Cabozantinib (Renal Cell Carcinoma)
Nivolumab + Ipilimumab (Renal Cell Carcinoma)
NCCN Guidelines for Patients®
JNCCN: How To Manage Cancer Care During COVID-19 Pandemic
Kidney Cancer Association